Cover Image
市場調查報告書

PharmaPoint:乾癬 - 全球醫藥品市場預測與市場分析

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 296456
出版日期 內容資訊 英文 307 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:乾癬 - 全球醫藥品市場預測與市場分析 PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
出版日期: 2016年04月13日 內容資訊: 英文 307 Pages
簡介

主要8個國家 (美國、EU5個國家、日本、印度) 的乾癬治療藥市場,預計2014年∼2024年以年複合成長率 (CAGR) 成長7.26%。

本報告提供乾癬治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明、安全性、有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 流行病學預測
    • 1年確診的患者數
    • 1年確診的患者數:各年齡
    • 1年確診的患者數:性別
    • 1年確診的患者數:年齡調整等
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷、治療概要
  • 美國
  • EU5個國家
  • 日本
  • 印度

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌

第7章 未滿足需求和機會

  • 概要
  • 患者利用的機會受限
  • 藥物的安全性、有效性的提高
  • 心理要素的教育和治療
  • 對不同的種類的乾癬相關醫生的教育

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床實驗:各階段、狀況
  • 臨床開發中的潛力藥物
  • 生技仿製藥的開發中產品

第9章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Johnson & Johnson
    • AbbVie
    • Amgen
    • Novartis
    • Pfizer
    • Eli Lilly
    • Merck
    • LEO Pharma
    • Celgene
    • Can-Fite Biopharma

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本
  • 印度

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC119PIDR

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-23 (IL-23) inhibitors (guselkumab and tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz, and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developments of biosimilars , are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

Highlights

Key Questions Answered

  • How good is the management of Psoriasis with marketed therapies?
  • Which drugs and players are important in the current management landscape?
  • What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the Psoriasis market?
  • What are the significant unmet needs and remaining opportunities in the Psoriasis market?
  • What clinical and commercial factors are likely to uptake of Psoriasis therapies in the US, 5EU, Japan and India?

Key Findings

  • The psoriasis market is currently very dynamic, with effective biologic therapies awaiting approval, such as interleukin-17 (IL-17) inhibitor- brodalumab, interleukin-23 (IL-23) inhibitors- guselkumab and tildrakizumab.
  • Novel biologic therapies will challenge the current anti-TNF biologics in an attempt to dislodge their stronghold, if their safety and efficacy profiles are proven once they enter the market.
  • The impending patent cliff for biologics will allow for the emergence of biosimilars to all the marketed biologic brands. Patent expiries take place during the forecast period for the current market leaders such as Johnson & Johnson's Remicade (infliximab), AbbVie's Humira (adalimumab), Amgen's Enbrel (etanercept) and Johnson & Johnson's Stelara (ustekinumab).
  • The drivers for market growth will also include affordable treatments throughout the world, as well as the push for long-term drug efficacy. The main challenge for individual drugs will be to distinguish themselves in a crowded marketplace, comprising a highly diversified field of therapies, with existing drugs struggling to increase their patient share.

Scope

  • Overview of Psoriasis, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
  • Topline Psoriasis market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the Psoriasis market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products- including promising IL-17 and IL-23 inhibitors.
  • Analysis of the current and future market competition in the global Psoriasis market (8MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Psoriasis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Psoriasis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. Prevalence
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used for One-Year Diagnosed Prevalence of Psoriasis
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods, One-Year Diagnosed Prevalent Cases of Psoriasis
  • 4.5. Epidemiological Forecast for Psoriasis (2014-2024)
    • 4.5.1. One-Year Diagnosed Prevalent Cases of Psoriasis
    • 4.5.2. Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis
    • 4.5.3. Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis
    • 4.5.4. Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis
    • 4.5.5. One-Year Diagnosed Prevalent Cases of Psoriasis by Severity
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Leading Prescribed Drugs and Treatment Guidelines
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan
  • 5.5. India

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Enbrel (Etanercept)
    • 6.3.2. Humira (Adalimumab)
    • 6.3.3. Remicade (Infliximab)
    • 6.3.4. Stelara (Ustekinumab)
    • 6.3.5. Cosentyx (Secukinumab)
    • 6.3.6. Taltz (Ixekizumab)
    • 6.3.7. Otezla (Apremilast)
    • 6.3.8. Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)
    • 6.3.9. Methotrexate
    • 6.3.10. Fumaderm (Fumaric Acid Esters)
    • 6.3.11. Alzumab (Itolizumab)
    • 6.3.12. Other Therapeutic Drug Classes Used in Psoriasis
    • 6.3.13. Non-pharmacological Therapy

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Limited Patient Access Due to Drug Reimbursement Pattern
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Improved Drug Safety and Efficacy Profiles
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Education and Treatment of Psychological Factors Accompanying Psoriasis
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising Drugs in Clinical Development
    • 8.4.1. Xeljanz (Tofacitinib)
    • 8.4.2. Brodalumab
    • 8.4.3. Guselkumab (CNTO-1959)
    • 8.4.4. Tildrakizumab
    • 8.4.5. Piclidenoson (CF-101)
    • 8.4.6. Additional Phase III Pipeline Products
    • 8.4.7. Phase II Pipeline Products
    • 8.4.8. Phase I Pipeline Products
  • 8.5. Biosimilar Pipeline Products
    • 8.5.1. Introduction
    • 8.5.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 8.5.3. Biosimilars in the Immunology Community
    • 8.5.4. By the Numbers: Biosimilars in Development
    • 8.5.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 8.5.6. Uptake of Biosimilars for Psoriasis is Expected to Vary by Market
    • 8.5.7. Biosimilars Forecast

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Johnson & Johnson
    • 9.3.2. AbbVie
    • 9.3.3. Amgen
    • 9.3.4. Novartis
    • 9.3.5. Pfizer
    • 9.3.6. Eli Lilly
    • 9.3.7. Merck
    • 9.3.8. LEO Pharma
    • 9.3.9. Celgene
    • 9.3.10. Can-Fite Biopharma

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. India
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Psoriasis Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Author
    • 11.7.2. Reviewer
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Director of Therapy Analysis and Epidemiology
    • 11.7.5. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Immune Cells Involved in Lesions
  • Table 2: Symptoms of Psoriasis
  • Table 3: Risk Factors and Comorbidities for Psoriasis
  • Table 4: 8MM, Global Trends for the Diagnosed Prevalence of Psoriasis
  • Table 5: 8MM, Sources of Epidemiological Data Used for the Forecast for Psoriasis One-Year Diagnosed Prevalent Cases
  • Table 6: 8MM, Sources of Epidemiological Data Used for the Segmentation of One-Year Diagnosed Prevalent Cases of Psoriasis by Severity
  • Table 7: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014-2024
  • Table 8: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N (Row %), 2014
  • Table 9: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N (Row %), 2014
  • Table 10: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis
  • Table 11: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2014
  • Table 12: Treatment Guidelines for Psoriasis
  • Table 13: Country Profile - US
  • Table 14: Country Profile - 5EU
  • Table 15: Country Profile - Japan
  • Table 16: Country Profile - India
  • Table 17: Leading Treatments for Psoriasis, 2015
  • Table 18: Product Profile - Enbrel
  • Table 19: Enbrel Pivotal Study I Outcomes at 3 and 6 Months
  • Table 20: Enbrel pivotal study II outcomes at 3 Months
  • Table 21: Long-Term Studies on Enbrel Efficacy in Treatment of Psoriasis
  • Table 22: Long-Term Safety Profile of Enbrel in the Treatment of Psoriasis
  • Table 23: Enbrel SWOT Analysis, 2015
  • Table 24: Global Sales Forecast ($m) for Enbrel, 2014-2024
  • Table 25: Product Profile - Humira
  • Table 26: Humira pivotal study outcomes at 16 weeks
  • Table 27: Humira SWOT Analysis, 2015
  • Table 28: Global Sales Forecast ($m) for Humira, 2014-2024
  • Table 29: Product Profile - Remicade
  • Table 30: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26
  • Table 31: Safety Results and AEs of RESTORE1 Trial of Remicade vs. MTX at Week 16
  • Table 32: Remicade SWOT Analysis, 2015
  • Table 33: Global Sales Forecast ($m) for Remicade, 2014-2024
  • Table 34: Product Profile - Stelara
  • Table 35: Stelara Pivotal Study Outcomes at Week 12
  • Table 36: Stelara SWOT Analysis, 2015
  • Table 37: Global Sales Forecast ($m) for Stelara, 2014-2024
  • Table 38: Product Profile - Cosentyx
  • Table 39: Efficacy Endpoints in Cosentyx Phase III ERASURE Study
  • Table 40: Efficacy End Points in Cosentyx Phase III FIXTURE study
  • Table 41: Cosentyx SWOT Analysis, 2015
  • Table 42: Global Sales Forecast ($m) for Cosentyx, 2014-2024
  • Table 43: Product Profile - Taltz
  • Table 44: Efficacy Results of UNCOVER-2 at Week 12
  • Table 45: Efficacy Results of UNCOVER-3 at Week 12
  • Table 46: Taltz SWOT Analysis, 2015
  • Table 47: Global Sales Forecast ($m) for Taltz, 2014-2024
  • Table 48: Product Profile - Otezla
  • Table 49: Otezla Efficacy Results at Week 16 in Studies ESTEEM-1 and ESTEEM-2
  • Table 50: Otezla SWOT Analysis, 2015
  • Table 51: Global Sales Forecast ($m) for Otezla, 2014-2024
  • Table 52: Product Profile - Taclonex/Enstilar
  • Table 53: Taclonex Efficacy Outcomes from Pivotal Phase III Studies for Adult Scalp and Body Psoriasis.
  • Table 54: Taclonex/Enstilar SWOT Analysis, 2015
  • Table 55: Global Sales Forecast ($m) for Taclonex/Daivobet/Dovobet, 2014-2024
  • Table 56: Product Profile - Methotrexate
  • Table 57: Methotrexate SWOT Analysis, 2015
  • Table 58: Global Sales Forecast ($m) for Methotrexate, 2014-2024
  • Table 59: Product Profile - Fumaderm
  • Table 60: Fumaderm SWOT Analysis, 2015
  • Table 61: Global Sales Forecast ($m) for Fumaderm, 2014-2024
  • Table 62: Product Profile - Alzumab
  • Table 63: Alzumab SWOT Analysis, 2013
  • Table 64: Global Sales Forecast ($m) for Alzumab, 2014-2024
  • Table 65: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2015
  • Table 66: Dosing Guidelines for Broadband Ultraviolet B
  • Table 67: Dosing Guidelines for Narrowband Ultraviolet B
  • Table 68: Overall Unmet Needs in Psoriasis - Current Level of Attainment
  • Table 69: Psoriasis - Clinical Trials by Phase and Status, 2015
  • Table 70: Psoriasis - Phase Pipeline, 2015
  • Table 71: Comparison of Therapeutic Classes in Development for Psoriasis, 2015
  • Table 72: Product Profile - Xeljanz
  • Table 73: Xeljanz SWOT Analysis, 2015
  • Table 74: Global Sales Forecast ($m) for Xeljanz, 2014-2024
  • Table 75: Product Profile - Brodalumab
  • Table 76: Brodalumab SWOT Analysis, 2015
  • Table 77: Global Sales Forecast ($m) for Brodalumab, 2014-2024
  • Table 78: Product Profile - Guselkumab
  • Table 79: Guselkumab SWOT Analysis, 2015
  • Table 80: Global Sales Forecast ($m) for Guselkumab, 2014-2024
  • Table 81: Product Profile - Tildrakizumab
  • Table 82: Tildrakizumab SWOT Analysis, 2015
  • Table 83: Global Sales Forecast ($m) for Tildrakizumab, 2014-2024
  • Table 84: Product Profile - Piclidenoson (CF-101)
  • Table 85: Piclidenoson SWOT Analysis, 2015
  • Table 86: Additional Phase III Psoriasis Pipeline drugs, 2015
  • Table 87: Phase II Psoriasis Pipeline, 2015
  • Table 88: Phase I Psoriasis Pipeline, 2015
  • Table 89: Marketed and Pipeline Biosimilars for Psoriasis in the 8MM, 2015
  • Table 90: Physician Uptake of Biosimilar Products for Psoriasis Across the 8MM, 2015
  • Table 91: Global Sales Forecast ($m) for Etanercept Biosimilars, 2014-2024
  • Table 92: Global Sales Forecast ($m) for Adalimumab Biosimilars, 2014-2024
  • Table 93: Global Sales Forecast ($m) for Infliximab Biosimilars, 2014-2024
  • Table 94: Key Companies in the Psoriasis Market, 2015
  • Table 95: J&J's Psoriasis Portfolio Assessment, 2015
  • Table 96: J&J's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 97: AbbVie's Psoriasis Portfolio Assessment, 2015
  • Table 98: AbbVie's Psoriasis SWOT Analysis, 2015
  • Table 99: Amgen's Psoriasis Portfolio Assessment, 2015
  • Table 100: Amgen's Psoriasis SWOT Analysis, 2015
  • Table 101: Novartis's Psoriasis Portfolio Assessment, 2015
  • Table 102: Novartis' Psoriasis SWOT Analysis, 2015
  • Table 103: Pfizer's Psoriasis Portfolio Assessment, 2015
  • Table 104: Pfizer's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 105: Eli Lilly's Psoriasis Portfolio Assessment, 2015
  • Table 106: Eli Lilly's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 107: Merck's Psoriasis Portfolio Assessment, 2015
  • Table 108: Merck's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 109: LEO Pharma's Psoriasis Portfolio Assessment, 2015
  • Table 110: LEO Pharma's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 111: Celgene's Psoriasis Portfolio Assessment, 2015
  • Table 112: Celgene's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 113: Can-Fite's Psoriasis Portfolio Assessment, 2015
  • Table 114: Celgene's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 115: Global Sales Forecast ($m) for Psoriasis, 2014-2024
  • Table 116: Global Psoriasis Market - Drivers and Barriers, 2014-2024
  • Table 117: Sales Forecast ($) for Psoriasis in the US, 2014-2024
  • Table 118: Key Events Impacting Sales for Psoriasis in the US, 2014-2024
  • Table 119: Psoriasis Market in the US - Drivers and Barriers, 2014-2024
  • Table 120: Sales Forecast ($) for Psoriasis in the 5EU, 2014-2024
  • Table 121: Key Events Impacting Sales for Psoriasis in the 5EU, 2014-2024
  • Table 122: Psoriasis Market in the 5EU - Drivers and Barriers, 2014-2024
  • Table 123: Sales Forecast ($) for Psoriasis in Japan, 2014-2024
  • Table 124: Key Events Impacting Sales for Psoriasis in Japan, 2014-2024
  • Table 125: Psoriasis Market in Japan - Drivers and Barriers, 2014-2024
  • Table 126: Sales Forecast ($) for Psoriasis in India, 2014-2024
  • Table 127: Key Events Impacting Sales for Psoriasis in India, 2014-2024
  • Table 128: Psoriasis Market in India - Drivers and Barriers, 2014-2024
  • Table 129: Key Launch Dates
  • Table 130: Key Patent Expiries
  • Table 131: Key Launch Dates
  • Table 132: Physicians Surveyed, by Country

List of Figures

  • Figure 1: Psoriatic Plaque on Elbow of Patient
  • Figure 2: The Three Layers of the Skin and Associated Structures
  • Figure 3: Healthy Skin Versus Psoriatic Skin
  • Figure 4: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014-2024
  • Figure 5: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N, 2014
  • Figure 6: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N, 2014
  • Figure 7: 8MM, Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis (%), All Ages, by Sex, 2014
  • Figure 8: 8MM, Severity Profile of One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, Both Sexes, N, 2014
  • Figure 9: Psoriasis Therapeutics - Ongoing Clinical Trial Sites by Country, 2015
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2014-2024
  • Figure 11: Biosimilar Prescribing Habits in Psoriasis Across the 8MM, 2015
  • Figure 12: Global Sales Forecast ($m) for Enbrel vs. Etanercept Biosimilars, 2014-2024
  • Figure 13: Global Sales Forecast ($m) for Humira vs. Adalimumab Biosimilars, 2014-2024
  • Figure 14: Global Sales Forecast ($m) for Remicade vs. Infliximab Biosimilars, 2014-2024
  • Figure 15: Company Portfolio Gap Analysis in Psoriasis, 2014-2024
  • Figure 16: Global Sales for Psoriasis by Region, 2014-2024
  • Figure 17: Sales for Psoriasis in the US by Drug Class, 2014-2024
  • Figure 18: Sales for Psoriasis in the 5EU by Drug Class, 2014-2024
  • Figure 19: Sales for Psoriasis in the 5EU by Region, 2014-2024
  • Figure 20: Sales for Psoriasis in Japan by Drug Class, 2014-2024
  • Figure 21: Sales for Psoriasis in India by Drug Class, 2014-2024
Back to Top